1. Scrip
  2. >>Leadership
  3. >>Executives On The Move

GSK Reorganizes Around Key R&D Areas As Lepore Exits

Therapy Area Research Units Created

 
• By Andrew McConaghie

The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.

New GSK House
• Source: GSK

GSK has unveiled a new R&D restructure to further increase productivity, creating dedicated teams for early-stage development in three key areas: vaccines and infectious diseases, respiratory/immunology and oncology.

A fourth priority area is HIV, which already has its own research team, within the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Executives On The Move

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.

Executives On The Move: Six CMOs, Five CEOs And Two CSOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Merck KGaA, Newleos Therapeutics and Artiva Biotherapeutics, plus Valo Therapeutics acquires chief executive officer from Johnson & Johnson.

More from Leadership